Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Personalized Neoantigen Vaccine Plus Third-line Therapy in CRC
NCT06751966Recruiting
- Sponsor
- First Affiliated Hospital of Nanchang University
- Start
- Sep 2024
- Primary completion
- Aug 2026
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of personalized tumor neoantigen-based peptide vaccine (Nanchang University) in colorectal cancer (CRC), sponsored by First Affiliated Hospital of Nanchang University. Primary endpoints: Objective Response Rate at 30 weeks, Disease Control Rate at 30 weeks and 1 more. Started Sep 2024; status: recruiting.
02
Drugs
personalized tumor neoantigen-based peptide vaccine (Nanchang University)
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT06751966.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06751966.